While Hims waits on BPC-157, a small pharmacy company says it has already sold one of HHS's six peptides
HHS's peptide policy has been on paper for less than two weeks. On November 9, 2026, a pharmacy company said it has moved it into the real world. DataMEDS AI, a Tampa company listed on Nasdaq, announced that Corexa Pharmacy, one of its subsidiaries, has made its first commercial sale of a peptide from the policy's list of six: BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. [V] It didn't say which one. Later that day, Hims & Hers told investors BPC-157 and TB-500 would come to its platform only "when the regulatory environment permits." [S] Two companies, one policy, two very different readings of the moment.
Facts are as of November 10, 2026. Sources, with retrieval dates, are at the bottom.
Updated November 11, 2026. A scoreboard of who has announced what — including Enhanced, Hims and DataMEDS — is in a new article.
What happened
- DataMEDS AI (Nasdaq: MEDS) says Corexa Pharmacy, its subsidiary, has made a first commercial sale of a peptide from HHS's list of six, under HHS's enforcement discretion policy. The release is dated November 9, 2026. [V]
- The company didn't name the peptide, the price or the volume. It says it's still working out pricing and plans to start marketing to prescribing physicians soon. [V]
- Its own release says the six are compounded drugs that aren't FDA-approved and haven't been evaluated by FDA for safety or effectiveness. [V]
- Public comments on the HHS policy close at 11:59 PM Eastern on Thursday, November 13. [V]
Why this one matters
Since HHS published its policy on October 30, the big question has been practical: would any licensed pharmacy actually step through the door it opened? Most of what we'd seen were plans. Hims said in late October that BPC-157 and TB-500 would follow "when allowable," and our November 3 article covered that. [S] On its November 9 earnings call, Hims put a date on a first phase of other products, later this month, and kept BPC-157 and TB-500 in the waiting line. Our Peptides+ article has the details. [S]
DataMEDS is saying something different: a sale has already happened. That makes it the first company we've seen publicly claim a completed sale of one of the six under the policy. [U] That's our reading of the coverage we've checked, not a claim the company made.
“compounded medications are prescribed on a one-to-one basis for individual patients”
That line matters because it's the core of how 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry compounding works. A state-licensed pharmacy fills a prescription written for one named patient. [V] The company says its marketing will be aimed at the physicians who write those prescriptions, not at the public, and that it intends to use its pharmacy hub and distribution warehouse to "take full advantage of the opportunity." [V]
The rules it says it's following
HHS's policy doesn't approve anything. It says HHS won't take enforcement action against licensed pharmacies, federal facilities and physicians that compound the six peptides under ten conditions. [V] The main ones, from our full breakdown of the policy:
- a valid prescription for a specific patient [V]
- one listed peptide per product, with the exact identity HHS spells out [V]
- ingredients from an FDA-registered maker that follows good manufacturing practice, with a certificate of analysis covering identity, purity, potency and contaminants [V]
- reports of serious side effects and quality problems to FDA's MedWatch program and the states [V]
- a label that reads "This is a compounded drug product. Not for resale." [V]
- limits on product forms: semax only as a nasal product, and KPV only in topical and oral forms [V]
DataMEDS says Corexa "has worked through the mechanics" of dispensing in line with the policy. [V] We have no way to check that from the outside, and the release doesn't describe the ingredient source or testing. [U] Our CGMP and certificates of analysis explainer shows what that paperwork is supposed to prove, and our USP brief covers why the standards body says none of the six has a public quality monograph yet. [V]
One detail in the release is worth a footnote. It describes the six as "recommended by" FDA's compounding advisory committee in July. The committee did vote in favor of each one. HHS's own appendix also records that FDA's drug center recommended against listing all six. [V] Our check of HHS's reasons against the research walks through both sides.
Who's behind it
DataMEDS AI was called Wellgistics Health until July 2026, according to its SEC filings. [V] It describes itself as a healthcare technology and pharmacy company, and it also owns a Pittsburgh cancer-testing lab. [V] In an October 22 filing, it said its Corexa Health unit has a distribution network of 6,500 independent pharmacies. [V] It's a small company: in an October 20 release, it said it had regained compliance with a Nasdaq rule requiring at least $2.5 million in stockholders' equity, after a delisting notice in April. [V]
The release's own risk list is unusually candid about what could go wrong. It names the chance that FDA or HHS changes or withdraws the policy, FDA's final decisions on the bulks list, the licensing still needed for its hub and warehouse, sterile compounding compliance, the quality of bulk ingredients, and competition from unregulated "research-use-only" products. [V]
- 6peptides covered by HHS's policy [V]
- 6,500independent pharmacies in Corexa Health's distribution network, per the company [V]
- Nov. 13last day for public comments on the policy [V]
What we don't know yet
- Which peptide. The release names all six but not the one that was sold. [V]
- Where. The release doesn't name the state the pharmacy shipped to or is licensed in. State pharmacy boards set their own rules on top of the federal policy. [V]
- Whether others have quietly started. Pharmacies don't have to announce sales, so a press release isn't a census. [U]
- How long the door stays open. HHS calls the policy interim and keeps the right to change or drop it. Part of the Federal Register notice describes it as a draft. [V]
Peptide Policy Watch
While Hims waits on BPC-157, a small pharmacy company says it has already sold one of HHS's six peptides
Printable checklist
What to ask at your next appointment
General questions drawn from this page, to take to a clinician or pharmacist who knows your health history.
- If you're suggesting a compounded peptide, which pharmacy makes it, and does it follow HHS's conditions?
- Can I see the label and the certificate of analysis for the ingredient?
- How would a side effect get reported, and who do I call?
- Is there an FDA-approved option for what we're treating?
Print view Select it, then use your browser’s Print command to print only this box.
What to watch next
Thursday is the first marker. When the comment period closes on November 13, we'll post the final tally from the docket hub. After that, three things: whether DataMEDS names the peptide and publishes its pricing, whether bigger players like Hims move BPC-157 or TB-500 off their waiting lists, and whether HHS keeps the policy as written. For where BPC-157 itself stands on four official lists, see Is BPC-157 FDA approved?, and for how a substance could reach the permanent list, see our 503A bulks list explainer. The first sale is the start of the story, not the end of it.
Sources (retrieved November 10, 2026)
- DataMEDS AI, "DataMEDS AI Announces Corexa Pharmacy's First Commercial Sale of Compounded Peptides Under FDA Enforcement Discretion Policy," ACCESS Newswire, November 9, 2026, 6:00 AM ET [V] — https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/datameds-ai-announces-corexa-pharmacys-first-commercial-sale-of-compo-1248766
- Hims & Hers Q3 2026 earnings call, November 9, 2026, third-party transcript (Benzinga) [S] — https://www.benzinga.com/news/26/11/63076365/hims-hers-health-q3-2026-earnings-call-transcript
- HHS, "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," with Appendices A and B [V] — https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf
- Federal Register, notice of availability, 91 FR 68526-68527, FR Doc. 2026-22192, Docket HHS-OASH-2026-0496, published October 30, 2026 [V] — https://www.federalregister.gov/documents/2026/10/30/2026-22192/enforcement-discretion-policy-regarding-503a-compounding-using-certain-peptide-bulk-drug-substances
- Regulations.gov, docket HHS-OASH-2026-0496 (comment period ends 11:59 PM Eastern, November 13, 2026) [V] — https://www.regulations.gov/docket/HHS-OASH-2026-0496
- SEC EDGAR, DataMeds AI, Inc. (CIK 0002030763) company filings index, showing former names Wellgistics Health, Inc. (to July 21, 2026) and Danam Health, Inc. [V] — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0002030763&type=8-K
- DataMEDS AI, Form 8-K Exhibit 99.1, "DataMEDS Regains Compliance with Nasdaq Listing Standards," October 20, 2026 [V] — https://www.sec.gov/Archives/edgar/data/2030763/000149315226047711/ex99-1.htm
- DataMEDS AI, Form 8-K Exhibit 99.1 (amended letter of intent; Corexa Health network of 6,500 independent pharmacies), October 22, 2026, filed October 26, 2026 [V] — https://www.sec.gov/Archives/edgar/data/2030763/000149315226048573/ex99-1.htm
- Hims & Hers newsroom, Andrew Dudum, "How we're building the customer relationship in health," November 9, 2026 [V] — https://news.hims.com/newsroom/how-were-building-the-customer-relationship-in-health
Cite or link to this page
Peptide Policy Watch staff. “While Hims waits on BPC-157, a small pharmacy company says it has already sold one of HHS's six peptides.” Peptide Policy Watch. Published November 10, 2026. Updated November 11, 2026. https://peptidepolicywatch.com/2026/11/10/datameds-corexa-first-sale-hhs-six-peptides/
Link: https://peptidepolicywatch.com/2026/11/10/datameds-corexa-first-sale-hhs-six-peptides/
Spot a mistake? See how we source and our corrections policy.
Image: AI-generated. Image credits